Clinical trials · Colorado
Hodgkin Lymphoma clinical trials in Colorado
We’re tracking 26 recruiting hodgkin lymphoma studies with a site in Colorado — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Colorado
- NCT07519772RecruitingPhase 1/Phase 2
Testing MK-1045 for Hard-to-Treat Lymphoma
This study tests a new drug called MK-1045 for people with follicular lymphoma or diffuse large B-cell lymphoma (two types of blood cancer) that hasn't responded to at least two previous treatments. The drug is designed to target cancer cells and may help people whose cancer has come back or stopped responding to therapy.
Denver, ColoradoAges 18 years+ - NCT07188558RecruitingPhase 3
Comparing ronde-cel to standard CAR T-cell therapy for large B-cell lymphoma
This trial tests a new treatment called ronde-cel against the usual CAR T-cell therapy for people with large B-cell lymphoma that has come back or not responded to initial treatment. The goal is to see if ronde-cel works better.
Denver, ColoradoAges 18 years+ - NCT06544265RecruitingPhase 1
SynKIR-310 for advanced B-cell lymphoma
This trial tests a new treatment called SynKIR-310 for people with B-cell non-Hodgkin lymphoma whose cancer has come back or not responded to at least 2 prior treatments. It may be an option if you've already had CAR T-cell therapy or cannot have it.
Denver, ColoradoAges 18 years+ - NCT06131801Recruiting
Crushed venetoclax tablet solution study for blood cancers
This study checks how the body handles venetoclax when it's given as a liquid made from crushed tablets. It's for children and young adults with blood cancers who already take venetoclax crushed or through a feeding tube.
Aurora, ColoradoAges birth–38 years - NCT05826535RecruitingPhase 1/Phase 2
Test of CAR T-cell therapy for aggressive B-cell lymphoma
This Phase 1/2 study tests a lab-made immune cell treatment (CAR T cells) made from your own blood cells to treat aggressive large B-cell lymphoma that has come back or didn’t respond. If you qualify, the goal is to see whether this treatment is safe and can shrink lymphoma.
Denver, ColoradoAges 18 years+ - NCT05798897RecruitingPhase 1
Study drug MT-601 for relapsed lymphoma patients
This early-phase trial tests MT-601 (an experimental treatment) in adults whose lymphoma has come back or didn’t respond to standard treatments. The study mainly checks safety, and it also looks for early signs that the treatment can shrink tumors.
Denver, ColoradoAges 18–100 - NCT05332054Enrolling by invitation
Long-term follow-up after prior Caribou treatment
This study checks your health over time after you previously took a Caribou medicine (or got it through a special access program). It helps researchers learn what happens in the longer run after the treatment.
Denver, ColoradoAges 18 years+ - NCT01351545Recruiting
Cryopreserved cord blood access program for transplant patients
This trial studies an organized way to obtain and distribute unlicensed (not FDA-approved for general use) stored cord blood units that have been frozen and kept. It may help people who need a cord blood transplant but don’t fit the “licensed cord blood only” options.
Denver, ColoradoAges Any age - NCT05098613RecruitingPhase 1
Testing a new immune cell therapy for relapsed B-cell lymphoma
This trial is testing a new treatment called CD19x22 CAR T cells for people with certain types of B-cell lymphoma that have come back or not responded to other treatments. The therapy uses your own immune cells, which are modified in a lab to better attack the cancer.
Aurora, ColoradoAges 16 years+ - NCT06098430Recruiting
Quality of life in NLPHL patients
This study looks at how people with a rare type of Hodgkin lymphoma (NLPHL) feel about their health and quality of life. By filling out surveys, you can help doctors understand what really matters to patients like you.
Aurora, ColoradoAges 8 years+ - NCT05006716RecruitingPhase 1/Phase 2
New treatment for blood cancers that have returned
This trial tests a new pill, tacabrutideg, for blood cancers that have returned or not improved after earlier treatments. It may work for patients who have already tried a type of targeted therapy called a BTK inhibitor.
Fort Collins, ColoradoAges 18 years+ - NCT07101328RecruitingPhase 1
Study of LY4152199 for Lymphoma That Returned or Didn't Respond
This study tests a new medicine called LY4152199 for people with certain types of lymphoma (follicular or diffuse large B-cell) that came back or didn't respond to previous treatment. The goal is to see if the drug is safe and how well it works.
Aurora, ColoradoAges 18 years+ - NCT05675410RecruitingPhase 3
Testing two-drug treatment versus standard for Hodgkin lymphoma
This Phase 3 study compares today’s standard treatment for classic Hodgkin lymphoma with a new combination using brentuximab vedotin and nivolumab. The goal is to see which approach works better and is safe for newly diagnosed patients with early-stage disease.
Aurora, ColoradoAges 5–60 - NCT05476770RecruitingPhase 1
Tagraxofusp for children with CD123-positive leukemia
This study tests tagraxofusp, a medicine that targets a marker called CD123 on cancer cells, in children and young adults whose leukemia or lymphoma has come back or is resistant to treatment. It may help by shrinking the cancer and improving disease control after standard therapies have not worked.
Denver, ColoradoAges 1–21 - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Aurora, ColoradoAges birth–18 years - NCT04851119RecruitingPhase 1/Phase 2
Tegavivint for kids and young adults with hard-to-treat solid tumors
This early-phase study tests tegavivint to see how well it works and how safe it is for children and young adults with solid cancers that have come back or are not responding. It may be an option if your tumor type (including certain lymphomas or desmoid tumors) matches the study’s rules.
Aurora, ColoradoAges 1–30 - NCT06533579RecruitingPhase 1/Phase 2
Gene therapy for CD19-positive blood cancers
This trial tests a new gene therapy treatment for people with certain types of leukemia or lymphoma that have the CD19 marker and have not responded to other treatments. The therapy uses a virus to deliver a gene to target and kill cancer cells.
Denver, ColoradoAges 13–90 - NCT07226843RecruitingPhase 1
Study of a new drug for adults with certain blood cancers
This trial tests a new drug, LY4584180, for adults with several types of non-Hodgkin lymphoma who have already had at least two prior treatments. The goal is to see if the drug can help shrink tumors and stop the cancer from growing.
Denver, ColoradoAges 18 years+ - NCT02332668RecruitingPhase 1/Phase 2
Pembrolizumab for children with advanced, hard-to-treat cancer
This trial tests pembrolizumab (an immunotherapy that helps the body recognize and attack cancer) in children with advanced solid tumors or lymphoma that can’t be cured. It’s designed for kids who have already tried standard treatments or don’t have standard treatment options.
Aurora, ColoradoAges 6 months–17 years - NCT04234048RecruitingPhase 1
ST-001 trial for stubborn T-cell lymphoma that came back
This Phase 1 trial tests ST-001, an experimental treatment, for T-cell lymphomas that have returned or did not respond to prior therapy. It aims to find a safe dose and see whether it can shrink or control the lymphoma.
Aurora, ColoradoAges 18 years+ - NCT03452774Recruiting
AI matches your cancer tests to possible treatment trials
This trial uses an AI system to help match people with certain cancer types and specific tumor test results (like gene or protein markers) to relevant clinical trials. It may help you and your doctor find studies that fit your cancer biology faster.
Aurora, ColoradoAges Any age - NCT06806033RecruitingPhase 2
Glofitamab alone or with chemo for relapsed aggressive b-cell lymphoma
This study tests two ways of giving a new drug called glofitamab — either alone or combined with chemotherapy (GemOx) — for people with aggressive B-cell lymphoma that has returned or not responded to previous treatment. The goal is to find a safer way to give the drug and to see if it helps control the cancer.
Aurora, ColoradoAges 18 years+ - NCT06418204Recruiting
Cannabis use among cancer patients in community clinics
This study looks at how cancer patients use cannabis (marijuana) and cannabis products to manage symptoms during chemotherapy or immunotherapy. The goal is to learn about the benefits and risks so doctors can better guide patients.
Aurora, ColoradoAges 18 years+ - NCT05425992Recruiting
Spanish-speaking families with leukemia or lymphoma
This study aims to improve communication and strengthen a child’s “medical home” (the main care team and coordination) for Spanish-speaking families. It focuses on families receiving cancer care at the Center for Cancer and Blood Disorders (CCBD).
Aurora, ColoradoAges Up to 22 years
Hodgkin Lymphoma trials by city in Colorado
Where these studies are running in Colorado
Institutions with a site for the recruiting hodgkin lymphoma studies listed above.
- Colorado Blood Cancer Institute · 8 studies
- Children's Hospital Colorado · 7 studies
- University of Colorado · 3 studies
- University of Colorado Hospital · 3 studies
- Rocky Mountain Cancer Centers · 2 studies
- University of Colorado Anschutz Medical Campus · 2 studies
- Call for Information (Investigational Site 0019)
- Cancer Care and Hematology-Fort Collins
What taking part in a hodgkin lymphoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Hodgkin Lymphoma trials in other states
Common questions
- Are there hodgkin lymphoma clinical trials in Colorado?
- Yes. We're currently tracking 26 recruiting hodgkin lymphoma studies with a site in Colorado, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a hodgkin lymphoma study in Colorado?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Colorado to take part?
- Not necessarily. These studies have a site in Colorado, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a hodgkin lymphoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New hodgkin lymphoma studies open in Colorado regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.